Chugai Pharmaceutical Co Ltd
4519: XTKS (JPN)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| JPY 6,951.00 | Thhnfs | Wxvyqtwqd |
Chugai's Cutting-Edge Antibody Platforms and Middle Molecule Programs Are Worth Watching
/s3.amazonaws.com/arc-authors/morningstar/0f2146bc-8a38-4a78-8fb8-fe1b37fb7287.jpg)
Business Strategy and Outlook
Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While current top products could see new branded and biosimilar threats over the next several years, the combined Roche-Chugai pipeline is robust and promising.